UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management
JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.
JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."
Pfizer closed at $27.99 on Tuesday.
Latest Ratings for PFE
|Dec 2016||Guggenheim||Initiates Coverage On||Neutral|
|Nov 2016||BMO Capital||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.